Mar 27, 2023
|
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
|
|
Mar 16, 2023
|
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
|
|
Mar 09, 2023
|
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
|
|
Feb 21, 2023
|
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
|
|
Feb 07, 2023
|
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
|
|
Jan 17, 2023
|
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
|
|
Jan 04, 2023
|
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
|
|
Dec 12, 2022
|
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
|
|
Dec 10, 2022
|
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
|
|
Dec 08, 2022
|
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
|
|
Nov 09, 2022
|
Vertex to Participate in Upcoming Investor Conferences
|
|
Nov 04, 2022
|
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
|
|
Nov 03, 2022
|
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
|
|
Oct 27, 2022
|
Vertex Reports Third Quarter 2022 Financial Results
|
|
Oct 13, 2022
|
Vertex to Announce Third Quarter 2022 Financial Results on October 27
|
|
Oct 11, 2022
|
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
|
|
Sep 27, 2022
|
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
|
|
Sep 08, 2022
|
Vertex Appoints Jonathan Biller as Chief Legal Officer
|
|
Sep 02, 2022
|
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
|
|
Aug 31, 2022
|
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
|
|